"As of December 31, 2018, our cash and cash equivalents were $2,634. We expect that our existing cash and cash equivalents will be sufficient to fund our current operations until May 31, 2019, without using the net proceeds from this offering and/or the net proceeds from the exercise of existing warrants. Effective October 1, 2018, we entered into the 2018 Credit Line, providing us with a credit line of $10 million. Furthermore, Dr. Yacov Geva, our President, Chief Executive Officer, Director and major shareholder has also undertaken to finance all of our financial needs until June 17, 2020."
- Forums
- ASX - By Stock
- GMV
- News: GMV G Medical Innovations Holdings Files For U.S. Listing Of Up To $17.3 Million
News: GMV G Medical Innovations Holdings Files For U.S. Listing Of Up To $17.3 Million, page-153
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online